ArticleFrontiers in cardiovascular medicine2026
Predictive value of electrocardiogram Morphology-Voltage-P wave duration score for new episodes of atrial fibrillation in patients with acute myocardial infarction: a retrospective study.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of atrial fibrillation (AF) is approximately 1.5%-2% of the general population. The Morphology-Voltage-P Wave Duration (MVP) score, a novel electrocardiographic tool based on Methods: This retrospective study included 334 patients treated for AMI from January 2018 to April 2021. Patients were categorized into low-risk (202 cases), medium-risk (98 cases), and high-risk (34 cases) groups based on MVP ECG scores. NOAF incidence, stratified as early-onset (≤48 h) and late-onset (>48 h), was tracked over a 12-month follow-up period. Statistical analyses included group comparisons, Cox regression for multivariate adjustment, ROC analysis to evaluate and compare the predictive performance of the MVP score against both the CHA₂DS₂-VASc and the AF-specific C2HEST scores, and decision curve analysis (DCA) to assess clinical utility. Results: The MVP ECG risk score effectively predicted long-term AF incidence, showing a graded increase in risk across categories: 11.9% in low-risk, 28.6% in medium-risk, and 76.5% in high-risk patients. Incidence increased for both early-onset (4.0%, 10.2%, 29.4%) and late-onset NOAF (7.9%, 18.4%, 47.1%). The MVP score demonstrated superior discriminative ability for total NOAF (AUC = 0.908) compared to the CHA₂DS₂-VASc score (AUC = 0.643) and the C2HEST score (AUC = 0.715), with the highest performance observed for late-onset NOAF (AUC = 0.925). Addition of the MVP score to either clinical score significantly improved reclassification (NRI: 0.28-0.35, IDI: 0.07-0.08). DCA confirmed that using the MVP score provided a greater net clinical benefit than the comparator scores across realistic decision thresholds. Multivariate analysis confirmed the MVP score as an independent predictor of AF, with a stronger association for late-onset events. Conclusion: The MVP ECG risk score is a simple, non-invasive tool that provides superior prediction of NOAF in AMI patients compared to traditional clinical risk scores, exhibiting particular strength in identifying patients at risk for late-onset AF. It effectively identifies high-risk patients who may benefit from close monitoring and proactive management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.